Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Thaçi D, Vender R, de Rie MA, Conrad C, Pariser DM, Strober B, Vanvoorden V, Wang M, Madden C, de Cuyper D, Kimball AB. Thaçi D, et al. Among authors: vender r. Br J Dermatol. 2023 Jan 23;188(1):22-31. doi: 10.1093/bjd/ljac021. Br J Dermatol. 2023. PMID: 36689515 Clinical Trial.
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
White S, Vender R, Thaçi D, Haverkamp C, Naeyaert JM, Foster R, Martinez Escribano JA, Cambazard F, Bibby A. White S, et al. Among authors: vender r. Am J Clin Dermatol. 2006;7(3):177-84. doi: 10.2165/00128071-200607030-00004. Am J Clin Dermatol. 2006. PMID: 16734505 Clinical Trial.
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J. Leonardi C, et al. Among authors: vender r. Arch Dermatol. 2011 Apr;147(4):429-36. doi: 10.1001/archdermatol.2010.384. Epub 2010 Dec 20. Arch Dermatol. 2011. PMID: 21173304 Clinical Trial.
A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin.
Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, Audibert F, Lynde C; POWER study group. Tan J, et al. Among authors: vender r. Br J Dermatol. 2014 Dec;171(6):1508-16. doi: 10.1111/bjd.13191. Epub 2014 Oct 28. Br J Dermatol. 2014. PMID: 24934963 Clinical Trial.
Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
Griffiths CE, Vender R, Sofen H, Kircik L, Tan H, Rottinghaus ST, Bachinsky M, Mallbris L, Mamolo C. Griffiths CE, et al. Among authors: vender r. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):323-332. doi: 10.1111/jdv.13808. Epub 2016 Sep 7. J Eur Acad Dermatol Venereol. 2017. PMID: 27600367 Free PMC article. Clinical Trial.
Biosimilars for psoriasis: clinical studies to determine similarity.
Blauvelt A, Puig L, Chimenti S, Vender R, Rajagopalan M, Romiti R, Skov L, Zachariae C, Young H, Prens E, Cohen A, van der Walt J, Wu JJ. Blauvelt A, et al. Among authors: vender r. Br J Dermatol. 2017 Jul;177(1):23-33. doi: 10.1111/bjd.15067. Epub 2017 May 28. Br J Dermatol. 2017. PMID: 27639072 Review.
231 results